Polaris Venture Management Co. V, L.L.C. - Q4 2020 holdings

$76.6 Million is the total value of Polaris Venture Management Co. V, L.L.C.'s 8 reported holdings in Q4 2020. The portfolio turnover from Q3 2020 to Q4 2020 was 11.1% .

 Value Shares↓ Weighting
FATE SellFate Therapeutics, Inc.$51,820,000
+51.7%
569,889
-33.3%
67.63%
+20.0%
LYRA  Lyra Therapeutics, Inc.$12,550,000
+2.0%
1,100,8520.0%16.38%
-19.3%
SELB  Selecta Biosciences, Inc.$8,404,000
+22.2%
2,773,4790.0%10.97%
-3.3%
XFOR  x4 Pharmaceuticals Inc.$2,003,000
-5.0%
311,4920.0%2.61%
-24.8%
LIFE  Atyr Pharma Inc.$507,000
+20.1%
130,5720.0%0.66%
-4.9%
GNCA  Genocea Biosciences, Inc.$478,000
+5.8%
197,3450.0%0.62%
-16.2%
DARE BuyDare Bioscience, Inc.$437,000
+34.0%
326,241
+0.0%
0.57%
+5.9%
PULM  Pulmatrix, Inc.$428,0000.0%359,4410.0%0.56%
-20.8%
STIM ExitNeuronetics, Inc.$0-732,583
-100.0%
-5.87%
Original filings

The following EDGAR filing(s) were analyzed to create this report:

  • View 13F-HR filed 2021-02-12
Signatures

The EDGAR filing(s) were signed by:

Top long-term holdings
NameQuarters ownedLatest quarter ownedMax weighting
Fate Therapeutics, Inc.30Q2 202179.2%
Atyr Pharma Inc.26Q3 202115.1%
Trevena, Inc.22Q2 201924.9%
Genocea Biosciences, Inc.21Q1 201932.5%
Selecta Biosciences, Inc.20Q1 202139.5%
T2 Biosystems, Inc.20Q2 201936.1%
Dare Bioscience, Inc.17Q3 20213.9%
Pulmatrix, Inc.16Q1 201915.4%
Cerulean Pharma Inc13Q2 201716.2%
Kala Pharmaceuticals, Inc.11Q1 202037.1%

View Polaris Venture Management Co. V, L.L.C.'s complete holdings history.

Latest filings
TypeFiled
32022-03-30
13F-HR2021-11-12
13F-HR2021-08-12
13F-HR2021-05-12
13F-HR2021-02-12
13F-HR2020-11-12
13F-HR2020-08-12
13F-HR2020-05-14
42020-05-06
32020-04-30

View Polaris Venture Management Co. V, L.L.C.'s complete filings history.

Compare quarters

Export Polaris Venture Management Co. V, L.L.C.'s holdings